1.12
-0.41 (-26.73%)
| Penutupan Terdahulu | 1.53 |
| Buka | 1.21 |
| Jumlah Dagangan | 6,566,256 |
| Purata Dagangan (3B) | 2,448,110 |
| Modal Pasaran | 6,793,679 |
| Harga / Buku (P/B) | 1.26 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -148,318.41% |
| EPS Cair (TTM) | 1.72 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.75% |
| Nisbah Semasa (MRQ) | 3.02 |
| Aliran Tunai Operasi (OCF TTM) | -10.24 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.32 M |
| Pulangan Atas Aset (ROA TTM) | -116.11% |
| Pulangan Atas Ekuiti (ROE TTM) | -208.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Azitra Inc | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| Persekitaran Makro | 0.0 |
| AI Insight | NA |
| Purata | -0.40 |
|
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 7.95% |
| % Dimiliki oleh Institusi | 4.52% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Dauntless Investment Group, Llc | 30 Jun 2026 | 1,129,219 |
| Stonepine Capital Management, Llc | 30 Jun 2026 | 528,548 |
| Nantahala Capital Management, Llc | 30 Jun 2026 | 221,361 |
| Tower Research Capital Llc (Trc) | 30 Jun 2026 | 1,950 |
| Corient Private Wealth Lp | 30 Jun 2026 | 1,445 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |